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Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signal trans-
duction mediates cytokine responses. Canonical signaling is based on STAT tyrosine 
phosphorylation by activated JAKs. Downstream of interferon (IFN) receptors, activated 
JAKs cause the formation of the transcription factors IFN-stimulated gene factor 3 
(ISGF3), a heterotrimer of STAT1, STAT2 and interferon regulatory factor 9 (IRF9) sub-
units, and gamma interferon-activated factor (GAF), a STAT1 homodimer. In recent years, 
several deviations from this paradigm were reported. These include kinase-independent  
JAK functions as well as extra- and intranuclear activities of U-STATs without phosphoty-
rosines. Additionally, transcriptional control by STAT complexes resembling neither GAF 
nor ISGF3 contributes to transcriptome changes in IFN-treated cells. Our review sum-
marizes the contribution of non-canonical JAK–STAT signaling to the innate antimicrobial 
immunity imparted by IFN. Moreover, we touch upon functions of IFN pathway proteins 
beyond the IFN response. These include metabolic functions of IRF9 as well as the 
regulation of natural killer cell activity by kinase-dead TYK2 and different phosphorylation 
isoforms of STAT1.
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iNTRODUCTiON
Since their discovery in the late 1950s (1), interferons (IFNs) have been assigned various functions 
that extend far beyond the initially observed antiviral activity. Three families of IFNs have been 
described and are known as type I (IFN-I, mainly IFNα/β), type II (IFN-II or IFNγ), and type III 
(IFN-III or IFNλ). In canonical IFN signaling, all types of IFNs produce a transcriptionally active 
signal transducer and activator of transcription 1 (STAT1) through receptor-bound Janus kinase 
(JAK)-mediated phosphorylation of tyrosine (Y) 701. The IFNγ receptor employs JAK1 and JAK2 
to phosphorylate exclusively STAT1, causing its homodimerization. STAT1 dimers, also called 
gamma interferon-activated factor (GAF), translocate to the nucleus and promote gene expression 
by binding to gamma interferon-activated site (GAS) of interferon-stimulated genes (ISG). On the 
other hand, stimulation with IFN-I or IFN-III leads to TYK2- and JAK1-mediated phosphorylation 
of STAT1 and STAT2. After forming heterodimers, these two proteins associate with interferon 
regulatory factor 9 (IRF9) to form a transcriptionally active IFN-stimulated gene factor 3 (ISGF3) 
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that controls gene expression by binding to interferon-stimulated 
response elements (ISRE) in a different set of ISGs (2, 3). Although 
a large majority of IFN-induced gene expression is mediated by 
canonical pathways, it has become clear that the components of 
these pathways are able to exert non-canonical activity: tyrosine 
kinase-independent action of JAKs, transcriptional complexes 
other than ISGF3 and GAF, and pathways building on U-STATs 
that are not phosphorylated on tyrosine. This review will focus 
on these non-canonical functions of JAK–STAT signaling 
components.
iFNs AND THeiR ROLe iN ReSiSTANCe 
TO viRUSeS AND BACTeRiA
As major components of the innate immune system against viral 
infections, all type I interferons (IFN-I) stimulate cell-autonomous 
antiviral activity (4). In addition, they increase cellular immunity 
through contributions to natural killer (NK) and T cell activation 
(5). IFN-I act as modulators of cellular immunity by selectively 
enhancing clonal expansion and survival of CD8+ T cells (6), 
directing the immune response toward Th1-dominace (7) and 
activating NK cells (8).
In the context of antibacterial defense, genes activated by 
IFN-I enhance inflammation and the death of infected cells (9). 
In addition, they impact on cells at the interface of the innate and 
adaptive immune systems, such as macrophages and dendritic 
cells, to increase antigen presentation and trigger the adaptive 
response (10). Immunostimulatory activities of IFN-I also 
contribute to immunosurveillance against cancer (11). On the 
other hand, their proinflammatory activity renders them driving 
forces behind a group of interferonopathies, such as the Aicardi-
Goutieres syndrome (12, 13).
While IFN-I are generally protective against viral infections, 
they can be both friend and foe in the defense of bacterial 
pathogens (14, 15). For example, IFN-I exert protective effects in 
the case of Chlamydia pneumoniae (16), Legionella pneumophila 
(17), Salmonella typhimurium (18), and both group A and group 
B Streptococcus infections (19–21). However, in infections with 
Listeria monocytogenes, Francisella tularensis, and Mycobacterium 
tuberculosis, production of IFN-I is associated with decreased 
innate immunity (22–27).
Major target cells of IFNγ are macrophages and T cells. 
Many of the genes induced by IFNγ are transcription factors, 
which amplify the transcriptional response and, as in Th cells, 
influence cell differentiation (28–30). IFNγ is particularly 
important in macrophage biology, where it provides cell-
autonomous antimicrobial activity through the upregulation of 
microbicidal gene products (31). Further, impact of IFNγ on 
macrophage activation results from its ability to synergize with 
or to antagonize the effects of different cytokines, growth factors, 
and pathogen-associated molecular pattern-signaling pathways 
(e.g., TNFα, IL-4, CSF-1, IFNα/β, LPS, and CpG DNA). Through 
these mechanisms, IFNγ activates macrophages to express anti-
microbial and antitumor effects. It upregulates chemokines and 
adhesion molecules, directing cells to the sites of inflammation. 
In the adaptive immunity, IFNγ plays an important role in Th1 
responses, repressing the development of Th2 and Th17 T cell 
responses (30) and acting directly on B cells to promote class 
switching from IgG2 to IgG3 (32). Mice and humans deficient 
in IFNγ or IFNGR1 show a decrease in natural resistance to 
bacterial, parasitic, and viral infections (33–35). Mice and cells 
lacking IFNγ display compromised tumor rejection, underlining 
its importance in tumor surveillance (11).
Discovered in the year 2003, IFN-III, better known as IFNλ, 
are the most recently described members of the IFN family 
(36). Although signaling through a different receptor complex 
with IFNλR/IL10R2 chains, IFNλ also stimulate formation of 
the ISGF3 complex. Given the similarities between the IFN-I 
and IFNλ signaling pathways, some of the non-canonical signals 
described below for IFN-I may apply to IFNλ as well. While IFNλ 
produce similar biological changes of their target cells as IFN-I, 
including antiviral, antiproliferative, and antitumor activity, the 
key to different organismic responses to IFN-III lies in their 
receptor distribution, which is prevalent on cells of epithelial 
origin (37). In line with that, defects in IFN-III production or 
signaling cause reduced innate immunity to viral pathogens 
replicating in epithelia of the lung and the gut. Mice lacking 
the IFN-I receptor are resistant to all IFN-I subtypes, but retain 
their sensitivity to IFN-III (38). However, studies performed in 
IFNAR1−/−, IL-28Rα−/−, and IFNAR1/IL-28Rα double knockout 
mice show that, in primary airway epithelia, upon influenza 
infection, IFN-I and IFN-III mediate parallel amplification 
loops that lead to the induction of fully overlapping groups of 
ISGs (39).
KiNASe-iNDePeNDeNT JAK ACTiviTY
Janus kinases are non-receptor tyrosine kinases which have 
essential roles in cytokine and growth factor signaling (40, 41). 
There are four different JAKs (JAK1, JAK2, JAK3, and TYK2) 
that cross-phosphorylate and activate each other when ligand-
associated cytokine receptor chains come in close proximity. 
Canonical, i.e., kinase-dependent functions of JAKs include tyros-
ine phosphorylation of receptor chains and of STATs at a single 
tyrosine residue near the C-terminal end. STAT phosphorylation 
is thought to require SH2 domain-mediated docking to the modi-
fied receptor chains, consistent with impaired phosphorylation at 
mutant receptors lacking the critical tyrosine for JAK-mediated 
phosphorylation (2).
Recently, reports studying kinase-inactive mutants of 
TYK2 and JAK2 suggest that these proteins exert functions 
not requiring their kinase activity and have important non-
canonical roles. Elegant studies in mouse models with kinase-
dead enzymes allow the demonstration of kinase-independent 
functions under physiologic conditions and complement stud-
ies in human and murine cell lines. Furthermore, description of 
naturally occurring mutations in JAKs in the human population 
broadens our understanding of the multifaceted role of JAKs in 
health and disease.
TYK2
TYK2 is involved in a large number of cytokine signaling 
cascades as it associates with the IFN-I (IFNAR), IL-12Rβ1, 
TABLe 1 | An overview of non-canonical Janus kinase (JAK)–signal 
transducer and activator of transcription (STAT) signaling by  
components of interferon (iFN) pathways.
Genotype Non-canonical STAT 
complexes
Function
WT overexpressing 
IFN-stimulated gene 
factor 3 (ISGF3) 
subunits
Unphosphorylated 
ISGF3 complex
Prolonged IFN-I responses, 
resistance to DNA damage
WT expressing high 
levels of STAT2
pYSTAT1/U-STAT2 Inhibition of STAT1 nuclear 
translocation, quenching of IFNγ 
response
STAT1Y701F STAT1Y701F/STAT2/? Inhibition of STAT2 nuclear 
translocation, quenching of type I 
IFN response
STAT1Y701F/? Natural killer (NK) cytotoxicity
STAT1S727A STAT1S727A dimer Reduction of IFNγ response
STAT1S727A/? NK cytotoxicity
STAT1−/− STAT2/interferon 
regulatory factor 9 
(IRF9)
Flavivirus and Legionella 
pneumophila resistance
STAT2−/− STAT1/IRF9 IFNγ—colitis, IFN-I—Legionella 
pneumophila resistance
TYK2K923E – NK cytotoxicity, mitochondrial 
respiration, IFNAR stability (in 
humans)
JAK2KD – IFN-gamma receptor stability, 
residual IFNγ response
“?” represents unknown interactors.
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IL-10R2, gp130, and IL13α1 receptor (42). Early work in 
human cell lines has demonstrated the important function of 
TYK2 in IFN-I signaling (43–46), as human cells fail to respond 
to IFNα in absence of TYK2. Furthermore, such cells display 
reduced IFNAR expression at the cell surface. Interestingly, 
this is a consequence of a non-canonical role of TYK2. The 
scaffold TYK2, but not its kinase or pseudokinase domains are 
needed for surface expression of IFNAR in human 11,1 cells 
(47). Specifically, TYK2 masks a tyrosine-based motif found 
in IFNAR, thereby shielding the receptor from endocytosis 
and preventing the binding of an enzyme (AP2), which leads 
to ubiquitin-dependent internalization (48). In this context, 
TYK2-receptor association requires neither ligand nor ubiqui-
tination. Preventing receptor degradation is a species-specific 
TYK2 activity, consistent with the lack of the Tyr-based motif 
in the murine IFNAR. However, TYK2 is not essential for IFN-I 
signaling in murine cells, and residual IFN-I activity is detected 
in the absence of this JAK (49, 50).
Mice with a targeted mutation of a critical lysine residue in 
the ATP-binding pocket of the TYK2 kinase domain (K923E) 
express a kinase-dead enzyme (51). Kinase-dead TYK2 shows 
a strongly reduced half-life owing to increased turnover via 
autophagosomal degradation. The reduced levels of TYK2K923E 
do not increase IFN-induced STAT activation above the level 
seen in the Tyk2−/− animals. Consistently, TYK2K923E mice are 
more susceptible to viral infections, comparable to Tyk2−/− mice. 
In contrast, TYK2K923E expression partially rescued the defect in 
natural killer cell (NK-cell) maturation and tumor killing that 
accompanies TYK2 deficiency (Table  1). At present, this first 
observation of a kinase-independent in vivo function of TYK2 
cannot be assigned to a defined NK signaling pathway. Other 
attributes of activated NK cells like IL-12 synthesis or activating 
receptor-stimulated production of IFNγ rely on TYK2 kinase 
activity (52).
Ligation of the IFNAR causes TYK2-dependent activation of 
the phosphoinositide 3 kinase (PI3K) pathway. Reportedly, this 
occurs without a need for TYK2 kinase activity (45). Moreover, 
in murine pro B cells, a part of TYK2’s functions in mitochondrial 
respiration is retained in absence of its kinase activity (53). The 
cells show a drastic defect in basal oxygen consumption and 
steady-state cellular ATP levels in the absence of TYK2, which 
can be reversed after transfection of wild-type or a kinase-dead 
mutant of TYK2 into these cells. In contrast, the kinase activity 
of TYK2 is required for other functions of mitochondria like 
complex I-mediated respiration and the induction of apoptosis 
after IFNβ treatment. TYK2 has also been linked to the energy 
expenditure of cells, to the regulation of lipid metabolism, dif-
ferentiation of brown adipose tissue, and obesity (54–56). In 
human obese patients and obese mice, decreased TYK2 levels are 
associated with increased obesity. This effect is regulated via Stat3 
signaling and prolonged stability of the transcriptional coactiva-
tor PRDM16, a master regulator of brown adipose tissue (55). 
The interaction of TYK2 with STAT3 is most probably a non-
canonical event, as tyrosine phosphorylation of STAT3 does not 
require TYK2. Therefore, the kinase must provide another kind 
of mechanistic input, either indirectly through other pathways or 
through another modification of STAT3.
The Tyk2 gene displays many different SNPs in the human 
population, and GWAS studies have linked mutations in Tyk2 
to autoimmune diseases like systemic lupus erythematosus, 
multiple sclerosis, Crohn’s disease, psoriasis, type I diabetes, 
endometriosis-related infertility, primary biliary cirrhosis, and 
rheumatoid arthritis (22–25, 57–68). The first patient described 
with Tyk2 mutation suffered from hyper-IgE syndrome (HIES) 
and presented with viral, bacterial, and mycobacterial infections. 
The role of TYK2 in several cytokine signaling pathways leads to 
these diverse susceptibilities, explained in part by a bias toward 
Th2 immunity and defective IL-12 and IFN-I pathways (26). 
Complementing this study, Kreins et al. described seven different 
patients from four different ethnic backgrounds with different 
mutations in Tyk2 (27). All patients examined so far had muta-
tions, deletions, or substitutions in the Tyk2 gene which ultimately 
led to a premature stop codon and no expression of Tyk2 protein. 
This group of patients did not present HIES. However, similar 
to the first patient, they suffered from widespread mycobacterial 
and viral infections. Using microarray analysis, Kreins et  al. 
demonstrated that, similar to TYK2-deficient mice, responses of 
the patient’s cells to various cytokines like IL-12, IFN-I, IL-23, 
and IL-10 are greatly reduced, but not completely abolished. This 
observation, made by the use of a sensitive detection method, 
might resolve the apparent discrepancy regarding the partial or 
absolute requirement of TYK2 for cytokine signaling in murine 
versus human cells. Another study described disease-associated 
human TYK2 variants, which are catalytically impaired, but able 
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to rescue signaling in response to IFN-I, IL-6, and IL-10 in vitro 
(69). The authors proposed a model for receptors associating with 
more than one JAK according to which only one JAK needs to 
be catalytically active in order to convey signals, as long as the 
second JAK functions as a scaffold.
JAK2
JAK2 is involved in many biological processes, including the 
growth control, survival, and differentiation particularly of 
hematopoietic cells. Accordingly, the widespread use of this 
kinase is reflected by the embryonic lethality of homozygous 
deletion (70, 71). The kinase activity of JAK2 is also implicated 
in various lymphoid and myeloid leukemias in which chromo-
somal translocation generates a hyperactive kinase (72–74). 
A scaffold function of JAK2 is suggested by the finding that 
the N-terminal domain of JAK2 alone is sufficient to enhance 
surface expression of the Epo receptor (EpoR) (75). Like Tyk2, 
mice expressing kinase-dead JAK2 were generated and resulted 
in the discovery of kinase-independent functions. Frenzel et al. 
generated a mouse model expressing a dominant-negative, 
kinase-inactive JAK2 by mutating residues in the C-terminal 
kinase domain (W1038G, E1046R) (76). This mouse mimics 
the complete loss of JAK2 as homozygous embryos die in utero. 
Heterozygous mice containing this dominant-negative form of 
Jak2 did not show any hematopoietic abnormalities, and it seems 
that one intact copy of Jak2 can compensate for the loss of kinase 
activity of the other, inactive form. Keil et  al. generated mice 
with inactive JAK2 by mutation of the activation loop tyrosines 
[JAK2YY1007/1008FF—(77)]. Similar to the mouse described by 
Frenzel et al., homozygous JAK2YY1007/1008FF alleles caused embry-
onic lethality and defective EpoR signaling, whereas heterozy-
gous mice appeared phenotypically normal. However, the study 
revealed a kinase-independent scaffolding function of JAK2 
for the heteromeric IFN-gamma receptor (IFNGR) complex. 
Importantly, JAK2YY1007/1008FF mediated the cell surface expression 
of the IFNGR indistinguishable from wild-type JAK2. Likewise, 
the recruitment of JAK1 to the receptor was normal. Contrasting 
Jak2-deficient cells, JAK1 alone was able to partly compensate 
for the loss of JAK2 signaling by phosphorylating STAT1 and 
inducing genes in response to IFNγ.
STAT1-iNDePeNDeNT ReSiSTANCe  
TO viRUSeS AND BACTeRiA—THe ROLe 
OF STAT2 AND iRF9
Experiments performed in cells and mice lacking functional 
STAT1 revealed its indispensable role in the IFN signaling path-
way. To date, mice lacking STAT1 have been challenged with at 
least 27 different pathogens and proved to be highly susceptible 
to most of the viruses, with exception of (+) single-strand RNA 
dengue virus (DENV) and the (−) single-strand RNA measles 
virus (MV). These mice are also highly susceptible to intracel-
lular bacteria, such as Listeria monocytogenes and Mycobacterium 
tuberculosis, and parasites such as Toxoplasma gondii and 
Leishmania major (78). Patients with complete autosomal reces-
sive STAT1 deficiency succumb to lethal mycobacterial and viral 
infections. Heterozygous autosomal recessive STAT1 deficiency 
also causes impaired IFN responses, but with milder clinical 
symptoms and more positive prognosis. Patients with autosomal 
dominant STAT1 loss-of-function mutations suffer from myco-
bacterial diseases and show an impaired response to IFNγ and 
IL-27 (78, 79). However, the majority of patients with inborn errors 
of STAT1 show autosomal dominant gain-of-function mutations 
leading to an unexpectedly broad clinical phenotype, including 
mucocutaneous candidiasis and autoimmune disorders (80, 81). 
In addition, some heterozygous de novo acquired mutations of 
the Stat1 gene, affecting coiled-coil and DNA-binding domains, 
can be associated with progressive combined immunodeficiency. 
This kind of Stat1 mutations lead to reduction in overall Stat1 
expression and signaling responses and are ultimately fatal due 
to overwhelming infections and inflammation (82).
While these findings emphasize the critical importance 
of STAT1 in IFN responses, studies in mice support the idea 
that residual IFN-dependent activity against some pathogens 
remains in absence of STAT1. Initial evidence for transcriptional 
responses to IFNs through non-canonical STAT complexes 
was provided by studies in Stat1−/− mice infected with Sendai 
virus, MCMV, or DENV, showing that STAT1-independent 
responses to IFNs provide some level of resistance against these 
pathogens (83–85). In contrast, the combined loss of IFNγ and 
type I IFN receptors or of STAT1 and STAT2 results in early 
death of infected mice (86, 87). Further, consistent with STAT1-
independent responses to IFN, Hahm et al. demonstrated that 
infection of hematopoietic bone marrow cells with MV or 
LCMV impaired the maturation of dendritic cells in an IFNβ-
dependent and Stat2-dependent, but STAT1-independent, man-
ner (88). Additional studies revealed that STAT2 was required 
for IFN-I-induced expression of a set of ISGs independently 
of STAT1 (85, 89, 90). Despite the inability to form ISGF3 
complexes, Stat1−/− mice and cells could still induce a subset 
of ISGs in response to the DENV infection (87). This response 
was absent in compound Stat1/2−/− mice, directing the main 
attention toward STAT2 as a component of STAT1-independent 
ISG expression in  vivo. STAT2 homodimers alone are known 
to bind DNA very poorly, owing to the lack of a functional 
DNA-binding domain (91). This suggests that one or more 
additional components must contribute to STAT1-independent 
ISG regulation. IRF9, the DNA-binding subunit of the ISGF3 
complex is an obvious candidate. The formation of STAT2–IRF9 
complexes after IFN-I stimulation had been proposed by several 
authors based on studies addressing ISG expression in HEK293 
cells with overexpressed STAT2 and IRF9 (91), in U3A cells that 
lack STAT1 (90), and in Hep3B cells (89). In addition, STAT2 
was shown to have a STAT1-independent role in the ability of 
IFNβ and TNFα to synergistically stimulate the expression of 
Duox2 NADPH oxidase in epithelial cell lines [(92), reviewed in 
detail in Ref (93, 94); Figure 1]. More recently, the potential of 
STAT2/IRF9 complexes to stimulate ISG emerged from studies 
addressing the role of type I IFN in bacterial infections.
As mentioned above, type I IFNs are secreted in response 
to many bacterial pathogens, such as Listeria monocytogenes, 
Francisella tularensis, Legionella pneumophila, and others (14, 
95–97). The impact of IFN-I on bacterial growth in mammalian 
FiGURe 1 | Canonical and non-canonical STAT signaling by the iFN receptors. Proposed roles of STAT or STAT/interferon regulatory factor (IRF9) complexes 
participating in signal transduction and transcriptional activation by the receptors of IFN-I, IFN-II or IFN-III. Complexes containing IRF9 associate with interferon-
stimulated response elements promoter sequences whereas dimerized STAT1 binds to GAS elements.
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hosts is variable, as described in detail elsewhere (14). In case of 
Legionella pneumophila, IFN-I inhibits its ability to grow inside 
macrophages. The growth inhibitory effect was retained in cells 
isolated from Stat1−/−, Stat2−/−, or Stat3−/− single knockout animals 
(17). In contrast, macrophages from compound Stat1/2−/− mac-
rophages were not able to limit the bacterial growth after IFN-I 
stimulation and had higher bacterial loads than single knockouts 
of STAT1 or STAT2, pinpointing redundant functions of STAT1 
and STAT2 in defense against this bacterial pathogen (98). Studies 
addressing the molecular mechanism of STAT1-independent ISG 
expression showed that IFN-I stimulated a delayed activation of 
STAT2 in Stat1−/− cells. Together with IRF9, STAT2 formed a 
complex able to bind to the ISRE sequence. Data in Stat1−/− mac-
rophages further demonstrated prolonged JAK activation by the 
IFN-I receptor and a slow but steady accumulation of both STAT2 
and pYSTAT2. The data were consistent with a model according 
to which a threshold of STAT2 phosphorylation needs to be over-
come for the formation of transcriptionally active STAT2–IRF9 
complexes and for delayed stimulation of ISG transcription 
(98, 99). This hypothesis has subsequently been validated in cells 
derived from mice expressing a STAT1Y701F mutant (99). It is 
further consistent with reports showing that STAT2 constitutively 
associates with IRF9 (100) and that this preassociation may be 
required for rapid generation of the ISGF3 in response to IFN 
signals in wt cells (101). All the findings together strongly sug-
gest that STAT2–IRF9-stimulated ISG expression could serve as 
a backup or a support mechanism of defense against pathogens 
that impede STAT1 signaling or serve to integrate the responses 
to IFN-I and TNFα (17, 84, 87, 92, 98).
NOveL ASPeCTS OF iFNγ SiGNALiNG BY 
CANONiCAL AND NON-CANONiCAL STAT 
COMPLeXeS
Canonical signaling by the IFNγ receptor causes the formation of 
GAF, the STAT1 homodimer. GAF activates gene transcription 
by associating with its cognate DNA-binding sequence, the GAS 
(2, 102). As in the case of IFN-γ, the reality of transcriptional 
responses to IFNγ adds complexity. In part, this is due to STAT1 
modification. The implications of Y701 phosphorylation as a 
dimerization signal are undisputed. Similarly, the enhancement 
of IFNγ-induced gene expression through phosphorylation of the 
C-terminal S727 and increased association with histone acetylase 
complexes are well documented (103, 104). Sumoylation of K703 
was first described by the group of Curt Horvath (105). The impli-
cations of this modification for STAT1 activation and activity 
were initially unclear (105, 106), but subsequent studies, particu-
larly those in cells derived from mice expressing SUMOylation-
defective STAT1, clearly linked SUMOylation to decreased IFNγ 
responsiveness (107, 108). Mechanistically, SUMOylation inter-
feres with the conjugation of a phosphate at the proximal Y701 
and increases nuclear tyrosine dephosphorylation by increasing 
STAT1’s solubility. In absence of the SUMO modification, STAT1 
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molecules assemble into an insoluble, phosphatase-resistant par-
acrystalline array (108, 109). Other than modification, the ability 
of STAT1 dimers to interact on DNA is essential for the expression 
of a large fraction of IFNγ-induced genes. This surprising finding 
emerged from studies in cells and mice expressing a STAT1F77A 
mutation that inhibits polymerization of promoter-bound STAT1 
dimers (110). Strikingly, responsiveness to type I IFN, hence the 
activity of the ISGF3 complex, was unaffected by the STAT1F77A 
mutation.
Further variety is introduced to the IFNγ pathway by asso-
ciation between STAT1 and other proteins, i.e., non-canonical 
complexes (Figure 1). Already in the 1990s, Ifit2, a classical ISRE-
regulated gene, was found to be induced by IFNγ in a STAT1- 
and IRF9-dependent, but STAT2-independent manner (111), 
suggesting that transcription factors containing both STAT1 
and IRF9 are able to control IFNγ-responsive genes. Affirmative 
observations were made for the expression of the Cxcl10 gene 
in IFNγ-stimulated 2fTGH cells (112). More recently, work from 
our lab identified an important role for STAT1/IRF9 in the con-
text of a murine colitis model (113). The Cxcl10 gene, known to 
contribute to colitogenic inflammation, was shown to be induced 
downstream of the IFNγ receptor in a STAT1/IRF9-dependent 
fashion, but independently of STAT2. Molecular analysis con-
firmed that STAT1/IRF9 complexes form in response to IFNγ and 
associate with ISRE sequences of enhancer regions 1 and 2 of the 
Cxcl10 gene promoter.
Other than STAT1/IRF9, STAT2 was proposed to contribute to 
IFNγ-induced transcription (Figure 1). The extent to which this 
occurs is unclear, owing in part to the fact that the lack of STAT2 
reduces STAT1 levels in some cell types, resulting in a mixed Stat1/
Stat2−/− phenotype. For example, Stat2−/− fibroblasts express little 
STAT1 and show impaired inhibition of vesicular stomatitis virus 
replication when treated with IFNγ (114). In support of a direct 
role for STAT2 in the IFNγ response, its tyrosine phosphoryla-
tion was reported in a study using IFNγ-treated wild-type mouse 
primary embryonic fibroblasts. This caused the formation of the 
ISGF3 transcription factor (115). Similar observations were made 
by Zimmerman and colleagues in MEFs (116). Stimulation of 
human lung epithelial cells with IFNγ triggered early and delayed 
peaks of STAT1 Y701 phosphorylation (117). The delayed peak 
corresponded to the formation of an ISGF3 complex, named 
ISGF3II, that contained Y701-phosphorylated STAT1 and IRF9, 
in addition to STAT2 that remained unphosphorylated on Y690. 
The idea of a STAT2 contribution to the delayed IFNγ response 
is in line with our recent finding that expression of the Cxcl10 
gene is decreased specifically at later stages of the IFNγ response 
in Stat2−/− macrophages (113). Consistently, we found STAT2 in 
association with the two Cxcl10 promoter ISREs at the delayed 
stage of the IFNγ response of wild-type macrophages. Of note, 
the same study shows that some genes with ISGF3 binding sites 
did not respond at any time to IFNγ in Stat2−/− macrophages. It 
appears possible, therefore, that both ISGF3 and ISGF3II com-
plexes contribute to IFNγ-induced transcription in a gene- and 
stage-specific manner. Of note, however, a stimulatory activity of 
ISGF3 and ISGF3II complexes is challenged by an entirely different 
perspective on the role of STAT2 (118). Ho and colleagues show 
a strong, N-terminal association between unphosphorylated 
STAT2 and STAT1. This association persists during the IFNγ 
response and prevents a fraction of STAT1 molecules to enter 
the nucleus (Figure  2). Consistently, mutations disrupting the 
N-terminal contacts increase the transcriptional IFNγ response. 
The study thus presents STAT2 as a moderator of IFNγ-activated 
STAT1. All findings together support both positive and negative 
regulation of IFNγ-induced transcription by STAT2. Our studies 
addressing the Cxcl10 gene suggest that this dual function of 
STAT2 may represent early and late phases of the transcriptional 
response to IFNγ, with initial repression being followed by stimu-
latory activity (110).
U-STAT CONTRiBUTiON TO  
THe iFN ReSPONSe
According to the original JAK–STAT paradigm, there is a strict 
correlation between STAT activity and their tyrosine phospho-
rylation. Defying this notion, numerous reports have meanwhile 
assigned important tasks to U-STATs lacking a phosphate at the 
critical tyrosine residue. U-STAT activities include control of 
organelle metabolism and function in mitochondria or the Golgi 
apparatus [STAT1, STAT2, and STAT3 and STAT6 in the biol-
ogy of mitochondria (119–125); STAT5 in the Golgi apparatus 
(125, 126)]. U-STAT1 was required for TNF-mediated apoptosis 
of U3A cells. This activity required the protein to be phosphoryl-
ated at the C-terminal S727 (127). To address potential functions 
of U-STAT1 in the immune system, we and our collaborators 
generated mice expressing a STAT1Y701F mutant and compared 
immune responses of these animals with Stat1−/− mice (99). 
Apart from a modest gain of function in antibacterial immunity 
described below, a notable difference was observed in NK cells. 
Whereas STAT1 deficiency led to a severe loss in NK cytotoxic-
ity, this is partially retained in Stat1Y701F mice (128). In contrast, 
U-STAT1 did not rescue the NK maturation defect observed in 
Stat1−/− mice. Localization to the NK-target cell interface hints at 
a potential role of U-STAT1 at the immunological synapse. NK 
cells also demonstrate a further non-canonical activity of STAT1 
related to its second phosphorylation site, the C-terminal S727. 
This site is a target for both p38MAPK and the S/T kinase CDK8 
(103, 129–131). Whereas in macrophages or fibroblasts S727 
phosphorylation increases the IFNγ-induced expression of a sub-
set of STAT1 target genes, CDK8-mediated S727 phosphorylation 
in NK cells restricts their cytotoxicity (132). Speculatively, the 
synaptic pool of STAT1 may be the relevant target, as Stat1S727A 
mutation in NK cells had little impact on their gene expression. 
In summary, NK cells reveal several non-canonical activities not 
only for STAT1, but, as described above, also for TYK2 (Table 1). 
The integration of these activities in cellular signaling networks 
remains a future challenge.
In addition to cytoplasm or organelle-based roles, nuclear 
functions were reported involving U-STATs as either gene repres-
sors or activators (133). For example, in Drosophila, STAT92E has 
been shown to associate with heterochromatin protein 1 (HP1) 
in cells lacking JAK activity, thus maintaining the structure of 
heterochromatin and gene repression (134, 135). Likewise, 
mammalian U-STAT5A reportedly binds to HP1α, stabilizing the 
FiGURe 2 | Levels of unphosphorylated signal transducer and activator of transcriptions (STATs) determine the strength of responses to type i iFN 
and iFNγ. The model is based on work published in references 99 and 118 showing that unphosphorylated STAT1 binds to tyrosine-phosphorylated STAT2 and 
vice versa. Such hemiphosphorylated STAT dimers are incapable of nuclear translocation (118). In the IFNγ response, unphosphorylated STAT2 thus lowers the 
formation and nuclear translocation of tyrosine-phoshorylated STAT1 dimers (118). Conversely, unphosphorylated STAT1 inhibits the nuclear translocation of 
tyrosine-phosphorylated STAT2 in the type I IFN response (99).
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heterochromatin in a similar fashion and repressing the genes 
involved in cancer development (136). In a more recent publica-
tion, mouse U-STAT5 was shown to actively repress the tran-
scriptional program required for megakaryocytic differentiation 
by preventing the binding of the transcriptional activator EGR, 
acting as a partial antagonist of biological activity of phosphoryl-
ated STAT5 (137). U-STAT3 was shown to compete with IκB for 
binding to unphosphorylated NFκB, translocating to the nucleus 
and participating in the activation of a subset of NFκB-dependent 
genes (138). U-STAT6, in cooperation with p300, was suggested 
to bind to a consensus STAT6 binding site in the promoter of 
the Cox-2 gene, regulating its constitutive expression (139). The 
mechanism by which the unphosphorylated STATs enter the 
nucleus remains to be explored. It is most likely related to the abil-
ity of unphosphorylated STATs to shuttle between nucleus and 
cytoplasm (140). While the nuclear export rate usually localizes 
most U-STATs in the cytoplasm at steady state, it is conceivable 
that some of these are trapped in the nucleus by DNA or chroma-
tin association. Other possibilities include the association with 
non-STAT transcription factors like IRF1, or direct contact with 
the nuclear pore complex (141–143).
The link between U-STATs and the IFN response was made by 
George Stark and colleagues. The group initially demonstrated an 
association of U-STAT1 and IRF1 with the partially overlapping 
interferon consensus sequence 2 and GAS sites in the promoter 
of the ISG Lmp2. This constitutive interaction resulted in expres-
sion of the Lmp2 gene in U3A cells (141). Additional studies, 
performed in cells overexpressing subunits of the ISGF3 complex, 
support the concept that U-STATs prolong the expression of a dis-
tinct subset of ISG (144) (Figure 3). The authors hypothesize that 
this occurs as a result of the accumulation of newly synthesized 
STAT1 and STAT2 following early, canonical type I IFN signal-
ing. According to this hypothesis, prolonged exposure of cells 
to IFN-I and accumulation of STAT1, STAT2, and IRF9 causes 
formation of an unphosphorylated ISGF3 complex (U-ISGF3), 
which in turn maintains the expression of a subset of ISGs that 
increase resistance to viruses and DNA damage (145).
We attempted to test the U-STAT1 model in Stat1Y701F mice (99). 
Indeed, some gain of function was noted when cells and animals 
expressing mutant STAT1 were infected with the bacterial patho-
gen Listeria monocytogenes and compared to STAT1-deficient 
counterparts. However, Starks U-STAT model could not be tested 
in these mice owing to the lack of an early, phosphotyrosine-based 
response to IFN-I that causes an increase of ISGF3 components 
(Figure 3). In fact, Stat1Y701F mutation caused a drastic decrease 
in basal levels of STAT1 in cells and animals, due to the lack of 
tonic signaling by the IFN-I receptor (99, 146). Thus, improved 
animal models expressing increased U-STAT amounts are needed 
to collect in vivo evidence for their function.
Of interest, the low amounts of U-STAT1 expressed in Stat1Y701F 
mice acted as suppressors of the delayed STAT1-independent, 
STAT2-dependent expression of ISGs after IFNβ stimulation 
(see above). This was a consequence of preventing cytoplasmic, 
tyrosine-phosphorylated STAT2 from entering the nucleus. The 
FiGURe 3 | U-STAT signaling in the type i iFN response. Early canonical signaling causes the upregulation of IFN-stimulated gene factor 3 (ISGF3) subunits and 
the subsequent formation of an ISGF3 complex with unphosphorylated signal transducer and activator of transcriptions 1 and 2 [unphosphorylated ISGF3 complex 
(U-ISGF3)]. U-ISGF3 stimulates a subset of interferon-stimulated genes to prolong the transcriptional response to IFN-I.
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data suggest that hemiphosphorylated STAT dimers do not show 
the enhanced nuclear translocation of the fully phosphorylated 
dimers. This notion is in line with the above-mentioned data from 
the Vinkemeier lab that demonstrate the inability of hemiphos-
phorylated dimers of wild-type STATs to enter the cell nucleus 
(118). Therefore, relative ratios of STAT1 and STAT2 and their 
phosphorylated isoforms may be an important determinant of 
nuclear signaling by the IFN receptors (Figure 2).
FUNCTiONS OF iRF9 BeYOND iFN 
SiGNALiNG
The studies described above assign an important function of IRF9 
to both IFN-I and IFNγ signaling. In this paragraph, we briefly 
describe some observations linking IRF9 to different diseases, 
either protecting from or exacerbating pathology. Notably, 
although IRF9 is an immune regulator, these data demonstrate 
additional mechanisms that may either link the immune system 
with these diseases or reflect IRF9 activities unrelated to the 
immune system. In most cases, the link to IFN signaling remains 
to be determined. The studies raise the possibility that IRF9 is 
capable of interacting with other transcription factors to fulfill a 
different set of functions (147).
Overexpression of IRF9 has been observed in breast and uterine 
tumors, where it provides resistance to microtubule-disrupting 
agents through transcriptional activation of ISGs in a STAT1- and 
STAT2-independent manner (148). In this situation, the ability 
of IL-6 to act as an inducer of IRF9 may be of importance, as 
shown for human prostate cancers (149). The role of IRF proteins 
in adipocyte biology connects the immune response with meta-
bolic regulation (150, 151). In obese mice IRF7 is increased (152), 
while the expression of IRF3 (153) and IRF9 (152) is decreased. 
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Thus, IRFs respond differently to overnutrition stress. In line with 
this, mice lacking IRF7 show improved hepatic insulin sensitivity 
and protection from local and systemic inflammation during 
high-fat diet (152). In contrast, IRF3 and IRF9 play a protective 
role in high-fat diet-induced obesity (153, 154). IRF9 was shown 
to interact with peroxisome proliferator-activated receptor α to 
regulate gene expression in the liver (154). Their target genes are 
mostly involved in lipid metabolism, thus attenuating insulin 
resistance in obese mice. This observation suggests a key role for 
IRF9 in metabolic functions.
Cardiac hypertrophy and pathological remodeling are hall-
marks of cardiomyopathy associated with many pathological 
stressors. Recent reports found that IRF3, IRF7, and IRF9 protect 
against cardiac hypertrophy (155–157). In murine disease mod-
els, IRF9 binds myocardin, an activator of the transcription factor 
serum response factor (SRF), thereby inhibiting SRF activation 
and associated proliferative response. Consistently, an aggravated 
cardiac hypertrophy occurs in Irf9−/− mice (157). Contrasting its 
protective effect in cardiac hypertrophy, upregulation of IRF9 
during myocardial ischemia–reperfusion (I/R) injury contributes 
to cardiomyocyte death and inflammation through the Sirt1–p53 
axis. In this context, the downregulation of the deacetylase SIRT1 
by IRF9 promotes apoptotic signaling through p53 (158). Similarly, 
IRF9 overexpression leads to cell death signaling in neurons in 
context of a cerebral ischemic stroke. Hence, IRF9 deficiency 
mitigates neurological deficits upon stroke (159). In arteria, IRF9 
mediates neointima formation, a scar that forms upon vascular 
injury. IRF9 overexpression increases, and its deficiency decreases 
the proliferation and migration of vascular smooth muscle cells 
(VSMCs). As in case of cardiomyocytes, IRF9 suppresses SIRT1 
by directly binding to an ISRE in the SIRT1 promoter. Thereby, 
IRF9 prevents the suppression of AP-1 transactivation by SIRT1. 
AP-1 induces a vascular injury response pathway that promotes 
VSMC proliferation in the context of neointima formation (160). 
Although critical roles of IRF9 in immunity, metabolism, and 
disease have been revealed, many questions regarding the mecha-
nisms by which IRF9 interconnects such a variety of pathways 
still remain.
CONCLUDiNG ReMARKS
The overwhelming biological impact of canonical JAK–STAT 
pathways is undisputed. However, as happens often in biological 
sciences, long shadows of paradigmatic signaling systems obscure 
alternative installations of their components for distinct purposes. 
Recent years of JAK–STAT research have begun to uncover some 
of these undogmatic events and establish them as non-canonical 
pathways side-by-side with the canonical ones. This provides 
food for thoughts about the evolution of JAK–STAT pathways, 
the emergence of non-canonical and canonical functions. 
Studies in Dictyostelium suggest that STATs evolved without the 
necessity for tyrosine phosphorylation or the ability to activate 
transcription (161). Thus, it is tempting to speculate that what 
we now perceive as a deviation from the canonical pathways is in 
reality closer to the primordial STAT function that had nothing 
to do with cytokines or the genes they activate. Although this 
review provides a very brief overview, we hope it allows readers 
to get an idea of the many different ways by which non-canonical 
JAK–STAT pathways are established in the mammalian immune 
system. Their analysis is far from easy, as results from straight-
forward experimental approaches are likely to be dominated by 
the pathway’s canonical output. In spite of this, future research 
with an open eye for the unexpected holds the promise of new 
fascinating insights into the many facets of JAKs and STATs in 
our immune system.
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